| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gout | 151 | 2024 | 618 | 36.920 |
Why?
|
| Uric Acid | 88 | 2024 | 803 | 14.600 |
Why?
|
| Hyperuricemia | 54 | 2024 | 224 | 13.800 |
Why?
|
| Gout Suppressants | 45 | 2024 | 177 | 10.220 |
Why?
|
| Allopurinol | 26 | 2024 | 198 | 7.640 |
Why?
|
| Hydroxychloroquine | 10 | 2024 | 426 | 3.850 |
Why?
|
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 13 | 2023 | 225 | 3.780 |
Why?
|
| Antirheumatic Agents | 28 | 2024 | 1368 | 3.220 |
Why?
|
| Arthritis, Rheumatoid | 49 | 2023 | 3755 | 3.080 |
Why?
|
| Chondrocalcinosis | 8 | 2023 | 82 | 2.820 |
Why?
|
| Lupus Erythematosus, Systemic | 13 | 2024 | 2159 | 2.710 |
Why?
|
| Rheumatology | 10 | 2023 | 611 | 2.680 |
Why?
|
| Arthritis, Psoriatic | 16 | 2021 | 219 | 2.610 |
Why?
|
| Rheumatic Diseases | 13 | 2022 | 639 | 2.270 |
Why?
|
| Arthritis, Gouty | 7 | 2021 | 28 | 2.050 |
Why?
|
| Nutrition Surveys | 21 | 2023 | 1716 | 2.040 |
Why?
|
| Psoriasis | 17 | 2021 | 938 | 1.960 |
Why?
|
| Diuretics | 9 | 2020 | 610 | 1.830 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 15 | 2023 | 288 | 1.820 |
Why?
|
| Retinal Diseases | 5 | 2024 | 702 | 1.750 |
Why?
|
| Incidence | 73 | 2024 | 21272 | 1.730 |
Why?
|
| Middle Aged | 228 | 2024 | 219568 | 1.700 |
Why?
|
| Sulfonylurea Compounds | 2 | 2024 | 219 | 1.630 |
Why?
|
| British Columbia | 22 | 2024 | 240 | 1.620 |
Why?
|
| Cohort Studies | 86 | 2024 | 41256 | 1.550 |
Why?
|
| Humans | 401 | 2024 | 758406 | 1.490 |
Why?
|
| Male | 256 | 2024 | 358747 | 1.480 |
Why?
|
| Calcium Pyrophosphate | 6 | 2023 | 53 | 1.450 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 4 | 2024 | 311 | 1.440 |
Why?
|
| Databases, Factual | 34 | 2024 | 7980 | 1.430 |
Why?
|
| Hospitalization | 16 | 2024 | 10652 | 1.420 |
Why?
|
| Kidney Failure, Chronic | 9 | 2023 | 2457 | 1.400 |
Why?
|
| Female | 254 | 2024 | 390323 | 1.380 |
Why?
|
| Myocardial Infarction | 23 | 2023 | 11424 | 1.380 |
Why?
|
| Aged | 162 | 2024 | 168218 | 1.360 |
Why?
|
| Pulmonary Embolism | 10 | 2023 | 2540 | 1.350 |
Why?
|
| Risk Factors | 113 | 2024 | 73809 | 1.350 |
Why?
|
| Venous Thrombosis | 10 | 2021 | 1292 | 1.350 |
Why?
|
| Diabetes Mellitus, Type 2 | 15 | 2024 | 12075 | 1.350 |
Why?
|
| Cause of Death | 15 | 2021 | 3675 | 1.320 |
Why?
|
| Fructose | 6 | 2011 | 287 | 1.300 |
Why?
|
| Hypertension | 24 | 2024 | 8499 | 1.250 |
Why?
|
| Alcohol Drinking | 19 | 2024 | 4018 | 1.190 |
Why?
|
| Calcinosis | 4 | 2023 | 1467 | 1.180 |
Why?
|
| Glucocorticoids | 11 | 2024 | 2144 | 1.170 |
Why?
|
| Polymyositis | 4 | 2021 | 75 | 1.160 |
Why?
|
| Lupus Nephritis | 3 | 2022 | 318 | 1.150 |
Why?
|
| Proportional Hazards Models | 39 | 2024 | 12440 | 1.140 |
Why?
|
| Cardiovascular Diseases | 25 | 2024 | 15399 | 1.140 |
Why?
|
| Obesity | 21 | 2021 | 12870 | 1.130 |
Why?
|
| Adult | 159 | 2024 | 219935 | 1.110 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 9 | 2018 | 3227 | 1.100 |
Why?
|
| Penicillins | 2 | 2019 | 406 | 1.020 |
Why?
|
| United States | 76 | 2024 | 72136 | 1.020 |
Why?
|
| Drug Eruptions | 2 | 2019 | 335 | 1.020 |
Why?
|
| Renal Insufficiency, Chronic | 8 | 2024 | 2239 | 1.000 |
Why?
|
| Giant Cell Arteritis | 6 | 2017 | 297 | 1.000 |
Why?
|
| Peroxidase | 6 | 2020 | 605 | 0.990 |
Why?
|
| Benzbromarone | 1 | 2024 | 7 | 0.970 |
Why?
|
| Dermatomyositis | 4 | 2021 | 256 | 0.950 |
Why?
|
| Diet | 23 | 2023 | 8005 | 0.950 |
Why?
|
| Ophthalmology | 3 | 2022 | 549 | 0.940 |
Why?
|
| Comorbidity | 24 | 2024 | 10495 | 0.930 |
Why?
|
| Diet, Mediterranean | 2 | 2022 | 736 | 0.930 |
Why?
|
| Recurrence | 14 | 2024 | 8426 | 0.930 |
Why?
|
| Colchicine | 4 | 2021 | 257 | 0.910 |
Why?
|
| Life Style | 12 | 2021 | 3886 | 0.900 |
Why?
|
| Body Mass Index | 29 | 2021 | 12876 | 0.900 |
Why?
|
| Remission Induction | 10 | 2023 | 2388 | 0.870 |
Why?
|
| Nephrolithiasis | 1 | 2024 | 114 | 0.850 |
Why?
|
| Venous Thromboembolism | 11 | 2022 | 1855 | 0.850 |
Why?
|
| Urolithiasis | 1 | 2024 | 132 | 0.840 |
Why?
|
| Risk | 21 | 2023 | 9599 | 0.840 |
Why?
|
| Beverages | 7 | 2011 | 819 | 0.840 |
Why?
|
| Population Surveillance | 5 | 2019 | 2606 | 0.840 |
Why?
|
| Genetic Predisposition to Disease | 16 | 2024 | 17768 | 0.830 |
Why?
|
| Histone Deacetylases | 5 | 2018 | 718 | 0.810 |
Why?
|
| Scleroderma, Systemic | 3 | 2016 | 344 | 0.800 |
Why?
|
| Apoptosis Regulatory Proteins | 6 | 2018 | 1134 | 0.790 |
Why?
|
| Spondylitis, Ankylosing | 3 | 2019 | 152 | 0.790 |
Why?
|
| Case-Control Studies | 41 | 2024 | 22029 | 0.760 |
Why?
|
| Alcoholic Beverages | 4 | 2010 | 264 | 0.760 |
Why?
|
| beta Carotene | 2 | 2013 | 523 | 0.750 |
Why?
|
| Prevalence | 24 | 2023 | 15651 | 0.750 |
Why?
|
| Drug Dosage Calculations | 2 | 2018 | 117 | 0.740 |
Why?
|
| Xanthine Oxidase | 2 | 2018 | 69 | 0.730 |
Why?
|
| Diabetes Mellitus | 11 | 2021 | 5816 | 0.720 |
Why?
|
| Follow-Up Studies | 35 | 2024 | 39059 | 0.720 |
Why?
|
| Prospective Studies | 47 | 2024 | 54137 | 0.690 |
Why?
|
| Coffee | 4 | 2010 | 582 | 0.690 |
Why?
|
| Cost of Illness | 6 | 2017 | 1936 | 0.690 |
Why?
|
| Stevens-Johnson Syndrome | 3 | 2020 | 244 | 0.690 |
Why?
|
| Drug Hypersensitivity | 2 | 2019 | 915 | 0.690 |
Why?
|
| Knee Joint | 6 | 2023 | 1663 | 0.670 |
Why?
|
| Neoplasm Proteins | 10 | 2024 | 3609 | 0.670 |
Why?
|
| Vitamin A | 2 | 2013 | 613 | 0.670 |
Why?
|
| Foot Joints | 1 | 2019 | 35 | 0.660 |
Why?
|
| Herpes Zoster Vaccine | 1 | 2019 | 49 | 0.660 |
Why?
|
| Stroke | 12 | 2023 | 9694 | 0.650 |
Why?
|
| Tramadol | 4 | 2020 | 60 | 0.650 |
Why?
|
| Joints | 3 | 2019 | 321 | 0.650 |
Why?
|
| Health Occupations | 1 | 2020 | 222 | 0.650 |
Why?
|
| Hand Joints | 1 | 2019 | 58 | 0.640 |
Why?
|
| Herpes Zoster | 2 | 2019 | 251 | 0.630 |
Why?
|
| Multivariate Analysis | 19 | 2020 | 12096 | 0.620 |
Why?
|
| Dairy Products | 4 | 2006 | 491 | 0.610 |
Why?
|
| Osteoarthritis | 8 | 2019 | 1055 | 0.610 |
Why?
|
| Hypoglycemic Agents | 5 | 2024 | 3069 | 0.610 |
Why?
|
| Uricosuric Agents | 4 | 2024 | 30 | 0.610 |
Why?
|
| Diet, Fat-Restricted | 1 | 2020 | 329 | 0.600 |
Why?
|
| Kidney Transplantation | 5 | 2022 | 4217 | 0.600 |
Why?
|
| Diet, Carbohydrate-Restricted | 1 | 2020 | 261 | 0.590 |
Why?
|
| Eye Diseases | 2 | 2022 | 651 | 0.580 |
Why?
|
| Renal Insufficiency | 1 | 2023 | 809 | 0.580 |
Why?
|
| Sex Factors | 15 | 2021 | 10504 | 0.570 |
Why?
|
| Biological Products | 4 | 2021 | 906 | 0.570 |
Why?
|
| Immunoglobulin G | 11 | 2023 | 4540 | 0.570 |
Why?
|
| Dietary Fiber | 1 | 2021 | 759 | 0.570 |
Why?
|
| Ascorbic Acid | 3 | 2009 | 655 | 0.560 |
Why?
|
| Cross-Over Studies | 9 | 2024 | 2048 | 0.560 |
Why?
|
| Osteoarthritis, Knee | 8 | 2022 | 1233 | 0.550 |
Why?
|
| Nuclear Receptor Co-Repressor 1 | 2 | 2013 | 28 | 0.550 |
Why?
|
| Phenylacetates | 1 | 2016 | 112 | 0.550 |
Why?
|
| Tomography, X-Ray Computed | 11 | 2024 | 20500 | 0.540 |
Why?
|
| Smoking | 12 | 2021 | 9051 | 0.540 |
Why?
|
| Metformin | 1 | 2024 | 907 | 0.540 |
Why?
|
| Insurance Claim Review | 2 | 2024 | 737 | 0.530 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 10 | 2019 | 2269 | 0.530 |
Why?
|
| Risk Reduction Behavior | 4 | 2021 | 1098 | 0.520 |
Why?
|
| Apathy | 1 | 2017 | 107 | 0.520 |
Why?
|
| Health Expenditures | 3 | 2020 | 2347 | 0.510 |
Why?
|
| Purines | 4 | 2012 | 605 | 0.500 |
Why?
|
| Artifacts | 1 | 2024 | 1897 | 0.500 |
Why?
|
| Sjogren's Syndrome | 1 | 2017 | 235 | 0.490 |
Why?
|
| Polymorphism, Single Nucleotide | 15 | 2024 | 15773 | 0.490 |
Why?
|
| Autoimmune Diseases | 5 | 2022 | 2244 | 0.490 |
Why?
|
| Tumor Suppressor Protein p53 | 6 | 2017 | 2912 | 0.490 |
Why?
|
| Health Care Costs | 3 | 2024 | 3245 | 0.480 |
Why?
|
| Propensity Score | 9 | 2024 | 1907 | 0.480 |
Why?
|
| Glucose Transport Proteins, Facilitative | 5 | 2024 | 57 | 0.480 |
Why?
|
| Erectile Dysfunction | 1 | 2018 | 451 | 0.480 |
Why?
|
| Acetamides | 1 | 2016 | 255 | 0.480 |
Why?
|
| Risk Assessment | 29 | 2024 | 23884 | 0.480 |
Why?
|
| Mendelian Randomization Analysis | 6 | 2024 | 993 | 0.470 |
Why?
|
| Cardiovascular Agents | 1 | 2021 | 839 | 0.470 |
Why?
|
| Cardiovascular System | 2 | 2020 | 835 | 0.470 |
Why?
|
| Commerce | 1 | 2020 | 604 | 0.470 |
Why?
|
| General Practice | 1 | 2015 | 96 | 0.460 |
Why?
|
| Aged, 80 and over | 35 | 2024 | 58683 | 0.460 |
Why?
|
| Cost-Benefit Analysis | 6 | 2017 | 5484 | 0.460 |
Why?
|
| Dietary Proteins | 3 | 2020 | 949 | 0.450 |
Why?
|
| Myocardial Ischemia | 4 | 2023 | 2108 | 0.450 |
Why?
|
| Registries | 7 | 2021 | 8175 | 0.440 |
Why?
|
| Sex Distribution | 9 | 2021 | 2284 | 0.440 |
Why?
|
| Canada | 4 | 2024 | 2111 | 0.430 |
Why?
|
| Prunus | 1 | 2012 | 10 | 0.430 |
Why?
|
| Caffeine | 3 | 2024 | 701 | 0.430 |
Why?
|
| Meat | 3 | 2005 | 584 | 0.430 |
Why?
|
| Primary Prevention | 1 | 2020 | 1185 | 0.420 |
Why?
|
| Immunologic Factors | 2 | 2019 | 1585 | 0.420 |
Why?
|
| Insulin Resistance | 4 | 2021 | 3941 | 0.420 |
Why?
|
| Menopause | 3 | 2010 | 1639 | 0.420 |
Why?
|
| Eating | 3 | 2021 | 1536 | 0.420 |
Why?
|
| Survival Rate | 8 | 2017 | 12721 | 0.410 |
Why?
|
| Estrogen Replacement Therapy | 2 | 2009 | 1206 | 0.410 |
Why?
|
| Dose-Response Relationship, Drug | 9 | 2024 | 10748 | 0.400 |
Why?
|
| DNA Damage | 4 | 2017 | 2439 | 0.390 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2018 | 694 | 0.390 |
Why?
|
| Arthritis, Infectious | 1 | 2015 | 345 | 0.390 |
Why?
|
| Feeding Behavior | 7 | 2014 | 3184 | 0.380 |
Why?
|
| Clostridium Infections | 1 | 2018 | 557 | 0.380 |
Why?
|
| Methotrexate | 6 | 2023 | 1719 | 0.380 |
Why?
|
| Health Status Disparities | 1 | 2023 | 1831 | 0.380 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2024 | 3175 | 0.370 |
Why?
|
| United States Food and Drug Administration | 4 | 2021 | 1659 | 0.370 |
Why?
|
| Sweetening Agents | 2 | 2010 | 290 | 0.370 |
Why?
|
| Multidrug Resistance-Associated Proteins | 2 | 2024 | 105 | 0.370 |
Why?
|
| Hospital Costs | 1 | 2017 | 960 | 0.370 |
Why?
|
| Mortality | 6 | 2019 | 2886 | 0.370 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2013 | 483 | 0.370 |
Why?
|
| Decision Support Techniques | 5 | 2016 | 1996 | 0.370 |
Why?
|
| Republic of Korea | 5 | 2024 | 565 | 0.360 |
Why?
|
| Vaccines | 1 | 2019 | 832 | 0.360 |
Why?
|
| Casein Kinase II | 4 | 2017 | 122 | 0.360 |
Why?
|
| Peripheral Vascular Diseases | 2 | 2014 | 488 | 0.360 |
Why?
|
| Diet Surveys | 6 | 2023 | 1161 | 0.350 |
Why?
|
| Managed Care Programs | 1 | 2015 | 939 | 0.340 |
Why?
|
| Medicaid | 2 | 2021 | 2807 | 0.340 |
Why?
|
| Cardiotonic Agents | 1 | 2013 | 539 | 0.340 |
Why?
|
| Practice Guidelines as Topic | 4 | 2022 | 7378 | 0.340 |
Why?
|
| Naproxen | 4 | 2019 | 100 | 0.340 |
Why?
|
| Severity of Illness Index | 20 | 2020 | 15785 | 0.330 |
Why?
|
| Staphylococcal Infections | 1 | 2018 | 1406 | 0.330 |
Why?
|
| Pilot Projects | 4 | 2021 | 8553 | 0.320 |
Why?
|
| Epidemiologic Methods | 7 | 2011 | 1338 | 0.320 |
Why?
|
| Research Design | 4 | 2017 | 6157 | 0.320 |
Why?
|
| Age Distribution | 8 | 2020 | 2882 | 0.320 |
Why?
|
| Cross-Sectional Studies | 17 | 2023 | 25956 | 0.320 |
Why?
|
| Tea | 2 | 2007 | 284 | 0.320 |
Why?
|
| Genome-Wide Association Study | 16 | 2024 | 12604 | 0.320 |
Why?
|
| Cyclophosphamide | 4 | 2023 | 2218 | 0.320 |
Why?
|
| Odds Ratio | 13 | 2021 | 9650 | 0.310 |
Why?
|
| Logistic Models | 11 | 2020 | 13276 | 0.310 |
Why?
|
| Coronary Disease | 4 | 2019 | 5917 | 0.310 |
Why?
|
| Immunosuppressive Agents | 4 | 2023 | 4158 | 0.310 |
Why?
|
| Women | 1 | 2010 | 225 | 0.310 |
Why?
|
| Probenecid | 2 | 2019 | 73 | 0.300 |
Why?
|
| Age Factors | 13 | 2019 | 18358 | 0.300 |
Why?
|
| Enzyme Inhibitors | 1 | 2018 | 3709 | 0.300 |
Why?
|
| Patient Education as Topic | 2 | 2019 | 2307 | 0.300 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2020 | 3432 | 0.290 |
Why?
|
| Young Adult | 23 | 2021 | 58808 | 0.290 |
Why?
|
| Vegetables | 3 | 2021 | 1195 | 0.290 |
Why?
|
| Protein Kinases | 1 | 2014 | 1610 | 0.290 |
Why?
|
| Healthcare Disparities | 1 | 2023 | 3364 | 0.290 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2015 | 973 | 0.290 |
Why?
|
| Urate Oxidase | 3 | 2024 | 31 | 0.290 |
Why?
|
| Spondylarthritis | 2 | 2018 | 58 | 0.290 |
Why?
|
| Retrospective Studies | 29 | 2024 | 80168 | 0.280 |
Why?
|
| Randomized Controlled Trials as Topic | 9 | 2022 | 10146 | 0.280 |
Why?
|
| Vaccination | 1 | 2019 | 3355 | 0.280 |
Why?
|
| Proton Pump Inhibitors | 2 | 2022 | 529 | 0.280 |
Why?
|
| Syndrome | 2 | 2023 | 3262 | 0.280 |
Why?
|
| Receptors, Thyroid Hormone | 1 | 2007 | 199 | 0.280 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2007 | 131 | 0.270 |
Why?
|
| Medicare | 4 | 2022 | 6741 | 0.270 |
Why?
|
| Body Weight | 5 | 2018 | 4603 | 0.270 |
Why?
|
| Treatment Outcome | 26 | 2024 | 64378 | 0.270 |
Why?
|
| Time Factors | 15 | 2021 | 39872 | 0.270 |
Why?
|
| Lipids | 3 | 2005 | 3326 | 0.260 |
Why?
|
| Fruit | 2 | 2021 | 1160 | 0.250 |
Why?
|
| Parathyroid Hormone | 1 | 2012 | 1797 | 0.250 |
Why?
|
| Longitudinal Studies | 15 | 2024 | 14490 | 0.250 |
Why?
|
| Stomach Neoplasms | 1 | 2015 | 1422 | 0.240 |
Why?
|
| Arthritis | 2 | 2014 | 666 | 0.240 |
Why?
|
| Myeloblastin | 4 | 2019 | 101 | 0.240 |
Why?
|
| HSP40 Heat-Shock Proteins | 2 | 2015 | 81 | 0.240 |
Why?
|
| Cholesterol, HDL | 7 | 2019 | 1808 | 0.240 |
Why?
|
| Fibroblasts | 1 | 2015 | 4087 | 0.240 |
Why?
|
| Weight Loss | 2 | 2020 | 2671 | 0.240 |
Why?
|
| Genetic Loci | 4 | 2021 | 2612 | 0.240 |
Why?
|
| Cholesterol | 8 | 2021 | 2902 | 0.230 |
Why?
|
| Bariatric Surgery | 1 | 2014 | 986 | 0.230 |
Why?
|
| Anti-Bacterial Agents | 3 | 2022 | 7403 | 0.230 |
Why?
|
| Polyethylene Glycols | 3 | 2024 | 1189 | 0.220 |
Why?
|
| Prognosis | 12 | 2021 | 29557 | 0.220 |
Why?
|
| Heart Failure | 4 | 2024 | 11593 | 0.220 |
Why?
|
| Sodium-Glucose Transporter 2 | 1 | 2024 | 89 | 0.220 |
Why?
|
| Waiting Lists | 2 | 2019 | 762 | 0.220 |
Why?
|
| Lactones | 2 | 2016 | 317 | 0.220 |
Why?
|
| Emergency Service, Hospital | 1 | 2023 | 7810 | 0.220 |
Why?
|
| Health Behavior | 2 | 2017 | 2617 | 0.220 |
Why?
|
| Antioxidants | 2 | 2008 | 1662 | 0.220 |
Why?
|
| Genetic Testing | 1 | 2016 | 3530 | 0.220 |
Why?
|
| Hip Fractures | 3 | 2023 | 987 | 0.220 |
Why?
|
| Actuarial Analysis | 1 | 2003 | 374 | 0.220 |
Why?
|
| Circadian Rhythm | 1 | 2015 | 2567 | 0.220 |
Why?
|
| Hospital Mortality | 1 | 2017 | 5272 | 0.210 |
Why?
|
| Insulin | 5 | 2024 | 6578 | 0.210 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2007 | 677 | 0.210 |
Why?
|
| Obesity, Morbid | 1 | 2014 | 1277 | 0.210 |
Why?
|
| Sodium, Dietary | 2 | 2016 | 425 | 0.210 |
Why?
|
| New Zealand | 3 | 2017 | 352 | 0.210 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2014 | 4342 | 0.210 |
Why?
|
| Patient Compliance | 1 | 2013 | 2685 | 0.210 |
Why?
|
| Transcriptional Activation | 2 | 2014 | 1752 | 0.210 |
Why?
|
| Systemic Vasculitis | 1 | 2023 | 36 | 0.210 |
Why?
|
| Phosphorylation | 6 | 2018 | 8297 | 0.210 |
Why?
|
| Fractures, Bone | 3 | 2017 | 2040 | 0.210 |
Why?
|
| Diet, Vegetarian | 1 | 2024 | 180 | 0.210 |
Why?
|
| Codeine | 2 | 2019 | 51 | 0.200 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2024 | 382 | 0.200 |
Why?
|
| Choice Behavior | 2 | 2005 | 821 | 0.200 |
Why?
|
| Xenopus laevis | 2 | 2024 | 965 | 0.200 |
Why?
|
| Markov Chains | 4 | 2017 | 965 | 0.200 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2004 | 361 | 0.200 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2007 | 727 | 0.200 |
Why?
|
| Sulfasalazine | 1 | 2002 | 84 | 0.200 |
Why?
|
| Arthroplasty, Replacement, Knee | 3 | 2019 | 1370 | 0.200 |
Why?
|
| Genetic Markers | 2 | 2020 | 2608 | 0.200 |
Why?
|
| Antihypertensive Agents | 1 | 2012 | 2016 | 0.200 |
Why?
|
| Obesity, Abdominal | 2 | 2019 | 374 | 0.200 |
Why?
|
| Quantitative Trait Loci | 2 | 2020 | 2100 | 0.200 |
Why?
|
| Sensitivity and Specificity | 10 | 2019 | 14641 | 0.200 |
Why?
|
| ATP-Binding Cassette Transporters | 3 | 2024 | 563 | 0.200 |
Why?
|
| Europe | 6 | 2019 | 3420 | 0.200 |
Why?
|
| California | 2 | 2024 | 1419 | 0.200 |
Why?
|
| Araliaceae | 1 | 2021 | 1 | 0.190 |
Why?
|
| Anticholesteremic Agents | 1 | 2009 | 963 | 0.190 |
Why?
|
| Receptors, Tumor Necrosis Factor | 3 | 2014 | 584 | 0.190 |
Why?
|
| Stomatitis | 1 | 2024 | 271 | 0.190 |
Why?
|
| Ambulatory Care | 1 | 2012 | 2768 | 0.190 |
Why?
|
| Adrenal Cortex Hormones | 4 | 2019 | 1870 | 0.190 |
Why?
|
| Epidemiologic Research Design | 1 | 2004 | 368 | 0.190 |
Why?
|
| Health Services Needs and Demand | 2 | 2020 | 1402 | 0.190 |
Why?
|
| Respiration, Artificial | 3 | 2021 | 2618 | 0.190 |
Why?
|
| Aspirin | 1 | 2013 | 3131 | 0.190 |
Why?
|
| Otorhinolaryngologic Diseases | 2 | 2019 | 95 | 0.180 |
Why?
|
| Thiazines | 2 | 2017 | 37 | 0.180 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2015 | 607 | 0.180 |
Why?
|
| Informatics | 1 | 2021 | 73 | 0.180 |
Why?
|
| Plant Leaves | 1 | 2021 | 150 | 0.180 |
Why?
|
| Isoxazoles | 1 | 2002 | 230 | 0.180 |
Why?
|
| Arthralgia | 2 | 2022 | 461 | 0.180 |
Why?
|
| Vitamins | 1 | 2009 | 1632 | 0.180 |
Why?
|
| IgG Deficiency | 1 | 2020 | 29 | 0.180 |
Why?
|
| Thiazoles | 3 | 2017 | 1510 | 0.180 |
Why?
|
| Biology | 1 | 2022 | 289 | 0.170 |
Why?
|
| HCT116 Cells | 3 | 2015 | 402 | 0.170 |
Why?
|
| Survival Analysis | 5 | 2020 | 10112 | 0.170 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2020 | 158 | 0.170 |
Why?
|
| Hyperinsulinism | 1 | 2023 | 400 | 0.170 |
Why?
|
| Adenosine | 1 | 2024 | 802 | 0.170 |
Why?
|
| Consensus | 5 | 2022 | 3099 | 0.170 |
Why?
|
| Crystallization | 2 | 2014 | 533 | 0.170 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2015 | 730 | 0.170 |
Why?
|
| Mikulicz' Disease | 1 | 2019 | 8 | 0.170 |
Why?
|
| Health Status | 4 | 2009 | 4071 | 0.160 |
Why?
|
| Azathioprine | 4 | 2023 | 356 | 0.160 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2006 | 831 | 0.160 |
Why?
|
| Organic Cation Transport Proteins | 2 | 2024 | 58 | 0.160 |
Why?
|
| Bone Malalignment | 1 | 2018 | 36 | 0.160 |
Why?
|
| Japan | 2 | 2024 | 1366 | 0.160 |
Why?
|
| Renal Replacement Therapy | 1 | 2021 | 281 | 0.160 |
Why?
|
| Retroperitoneal Fibrosis | 1 | 2019 | 42 | 0.160 |
Why?
|
| Repressor Proteins | 3 | 2016 | 2980 | 0.160 |
Why?
|
| Triglycerides | 5 | 2010 | 2451 | 0.160 |
Why?
|
| Disease Management | 3 | 2018 | 2500 | 0.160 |
Why?
|
| Central Nervous System Stimulants | 1 | 2007 | 1176 | 0.160 |
Why?
|
| Ubiquitination | 4 | 2015 | 1006 | 0.150 |
Why?
|
| Organic Anion Transporters | 2 | 2024 | 100 | 0.150 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 2 | 2017 | 320 | 0.150 |
Why?
|
| Health Personnel | 5 | 2017 | 3312 | 0.150 |
Why?
|
| Apolipoprotein A-I | 3 | 2019 | 294 | 0.150 |
Why?
|
| Stress, Physiological | 2 | 2017 | 1398 | 0.150 |
Why?
|
| Health Resources | 1 | 2024 | 931 | 0.150 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2021 | 597 | 0.150 |
Why?
|
| Aortitis | 1 | 2019 | 74 | 0.150 |
Why?
|
| Israel | 1 | 2020 | 721 | 0.150 |
Why?
|
| Eosinophilia | 1 | 2022 | 559 | 0.150 |
Why?
|
| Sodium | 1 | 2023 | 1588 | 0.150 |
Why?
|
| Adolescent | 17 | 2021 | 87892 | 0.150 |
Why?
|
| Enzyme Activation | 2 | 2014 | 3593 | 0.150 |
Why?
|
| Nutrition Policy | 1 | 2022 | 470 | 0.150 |
Why?
|
| Random Allocation | 1 | 2022 | 2385 | 0.150 |
Why?
|
| Pain | 2 | 2023 | 5065 | 0.150 |
Why?
|
| Anti-Obesity Agents | 1 | 2021 | 227 | 0.150 |
Why?
|
| Diclofenac | 4 | 2019 | 67 | 0.150 |
Why?
|
| Parkinson Disease | 2 | 2008 | 2862 | 0.150 |
Why?
|
| Plant Extracts | 1 | 2021 | 489 | 0.150 |
Why?
|
| Dermatologic Agents | 1 | 2021 | 308 | 0.150 |
Why?
|
| C-Reactive Protein | 5 | 2022 | 3812 | 0.140 |
Why?
|
| Overweight | 3 | 2019 | 2411 | 0.140 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2020 | 540 | 0.140 |
Why?
|
| Digestive System Diseases | 1 | 2019 | 151 | 0.140 |
Why?
|
| Delivery of Health Care | 1 | 2015 | 5331 | 0.140 |
Why?
|
| Life Expectancy | 1 | 2004 | 1244 | 0.140 |
Why?
|
| Agammaglobulinemia | 1 | 2018 | 173 | 0.140 |
Why?
|
| Nurses | 4 | 2021 | 2467 | 0.140 |
Why?
|
| Vaccines, Synthetic | 1 | 2019 | 617 | 0.140 |
Why?
|
| Sulfinpyrazone | 1 | 2016 | 15 | 0.140 |
Why?
|
| Gastroesophageal Reflux | 1 | 2024 | 816 | 0.140 |
Why?
|
| Cell Line, Tumor | 12 | 2016 | 16886 | 0.140 |
Why?
|
| Diet, Reducing | 1 | 2020 | 485 | 0.140 |
Why?
|
| Drinking Behavior | 2 | 2007 | 103 | 0.140 |
Why?
|
| Carnitine O-Palmitoyltransferase | 1 | 2016 | 83 | 0.140 |
Why?
|
| Transducin | 1 | 2016 | 42 | 0.140 |
Why?
|
| Prostatic Neoplasms | 3 | 2016 | 11336 | 0.140 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2020 | 788 | 0.140 |
Why?
|
| Patients | 1 | 2003 | 904 | 0.140 |
Why?
|
| Quality of Life | 7 | 2021 | 13285 | 0.140 |
Why?
|
| Population Growth | 1 | 2016 | 50 | 0.140 |
Why?
|
| Hypolipidemic Agents | 1 | 2021 | 609 | 0.140 |
Why?
|
| Clinical Coding | 2 | 2016 | 180 | 0.130 |
Why?
|
| Prehypertension | 1 | 2016 | 63 | 0.130 |
Why?
|
| Analgesics, Opioid | 4 | 2020 | 3765 | 0.130 |
Why?
|
| Thioredoxin Reductase 2 | 1 | 2016 | 25 | 0.130 |
Why?
|
| Hydrolyzable Tannins | 1 | 2015 | 10 | 0.130 |
Why?
|
| Disease Progression | 5 | 2019 | 13468 | 0.130 |
Why?
|
| Poisson Distribution | 1 | 2017 | 505 | 0.130 |
Why?
|
| Hand | 2 | 2015 | 903 | 0.130 |
Why?
|
| Infusions, Intravenous | 1 | 2020 | 2210 | 0.130 |
Why?
|
| Sumoylation | 1 | 2016 | 83 | 0.130 |
Why?
|
| Co-Repressor Proteins | 2 | 2013 | 191 | 0.130 |
Why?
|
| Terminology as Topic | 3 | 2019 | 1533 | 0.130 |
Why?
|
| Drugs, Generic | 1 | 2021 | 444 | 0.130 |
Why?
|
| Molecular Targeted Therapy | 3 | 2017 | 2796 | 0.130 |
Why?
|
| Glycoproteins | 1 | 2023 | 2205 | 0.130 |
Why?
|
| Delphi Technique | 1 | 2019 | 829 | 0.130 |
Why?
|
| Hyperlipidemias | 2 | 2018 | 772 | 0.120 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2017 | 330 | 0.120 |
Why?
|
| Caspase 7 | 1 | 2014 | 49 | 0.120 |
Why?
|
| Diet, Sodium-Restricted | 1 | 2016 | 291 | 0.120 |
Why?
|
| Weight Gain | 1 | 2005 | 2346 | 0.120 |
Why?
|
| Acetylation | 2 | 2014 | 1060 | 0.120 |
Why?
|
| Karyopherins | 1 | 2015 | 130 | 0.120 |
Why?
|
| Nutritional Status | 1 | 2023 | 1607 | 0.120 |
Why?
|
| Drug Administration Schedule | 4 | 2019 | 4839 | 0.120 |
Why?
|
| Wrist Injuries | 1 | 2017 | 214 | 0.120 |
Why?
|
| HeLa Cells | 2 | 2013 | 3096 | 0.120 |
Why?
|
| Joint Diseases | 1 | 2018 | 457 | 0.120 |
Why?
|
| Lysophospholipase | 1 | 2014 | 65 | 0.120 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2015 | 609 | 0.120 |
Why?
|
| Magnesium | 1 | 2017 | 809 | 0.110 |
Why?
|
| Cytoplasm | 2 | 2019 | 1514 | 0.110 |
Why?
|
| Rheumatoid Factor | 2 | 2005 | 185 | 0.110 |
Why?
|
| Vasculitis | 3 | 2003 | 522 | 0.110 |
Why?
|
| Knee Injuries | 1 | 2018 | 489 | 0.110 |
Why?
|
| Active Transport, Cell Nucleus | 2 | 2013 | 435 | 0.110 |
Why?
|
| Radiography | 6 | 2023 | 6954 | 0.110 |
Why?
|
| Drug Approval | 1 | 2021 | 808 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2023 | 2443 | 0.110 |
Why?
|
| Lipid Metabolism | 2 | 2019 | 1895 | 0.110 |
Why?
|
| Alzheimer Disease | 1 | 2015 | 8544 | 0.110 |
Why?
|
| Gallstones | 1 | 2016 | 283 | 0.110 |
Why?
|
| Humidity | 1 | 2014 | 205 | 0.110 |
Why?
|
| Glucose | 2 | 2023 | 4336 | 0.110 |
Why?
|
| Genetic Variation | 3 | 2017 | 6548 | 0.110 |
Why?
|
| Catechin | 1 | 2013 | 69 | 0.110 |
Why?
|
| Immunoprecipitation | 1 | 2015 | 877 | 0.100 |
Why?
|
| Hypersensitivity | 1 | 2022 | 1155 | 0.100 |
Why?
|
| Smad2 Protein | 1 | 2013 | 145 | 0.100 |
Why?
|
| DNA-Binding Proteins | 2 | 2024 | 9574 | 0.100 |
Why?
|
| Smad3 Protein | 1 | 2013 | 166 | 0.100 |
Why?
|
| Protein Binding | 6 | 2015 | 9311 | 0.100 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2014 | 444 | 0.100 |
Why?
|
| Kidney | 4 | 2023 | 7016 | 0.100 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2015 | 857 | 0.100 |
Why?
|
| Blood Sedimentation | 3 | 2019 | 234 | 0.100 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2016 | 577 | 0.100 |
Why?
|
| Pharmacoepidemiology | 1 | 2016 | 350 | 0.100 |
Why?
|
| Selection Bias | 1 | 2014 | 357 | 0.100 |
Why?
|
| Range of Motion, Articular | 1 | 2018 | 1583 | 0.100 |
Why?
|
| Disability Evaluation | 4 | 2009 | 1825 | 0.100 |
Why?
|
| Kidney Diseases | 2 | 2020 | 2083 | 0.100 |
Why?
|
| Signal Transduction | 9 | 2016 | 23342 | 0.100 |
Why?
|
| Linear Models | 3 | 2019 | 5862 | 0.100 |
Why?
|
| Endothelium, Vascular | 2 | 2018 | 4429 | 0.100 |
Why?
|
| Consanguinity | 1 | 2014 | 456 | 0.100 |
Why?
|
| Animals | 18 | 2024 | 167768 | 0.100 |
Why?
|
| Cooking | 1 | 2014 | 311 | 0.100 |
Why?
|
| Kallikreins | 1 | 2013 | 230 | 0.100 |
Why?
|
| Patient Care Team | 2 | 2020 | 2504 | 0.100 |
Why?
|
| Adiposity | 1 | 2021 | 1858 | 0.100 |
Why?
|
| Blood Pressure | 3 | 2016 | 8451 | 0.100 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2016 | 855 | 0.100 |
Why?
|
| Organic Anion Transporters, Sodium-Independent | 2 | 2024 | 28 | 0.100 |
Why?
|
| Cartilage, Articular | 1 | 2019 | 1091 | 0.100 |
Why?
|
| Transfection | 3 | 2014 | 5779 | 0.100 |
Why?
|
| Anti-Infective Agents | 1 | 2019 | 981 | 0.100 |
Why?
|
| Autoantibodies | 1 | 2020 | 2118 | 0.100 |
Why?
|
| Neoplasm Transplantation | 1 | 2015 | 2013 | 0.090 |
Why?
|
| Osteoarthritis, Hip | 1 | 2015 | 406 | 0.090 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2017 | 1972 | 0.090 |
Why?
|
| Seafood | 2 | 2005 | 390 | 0.090 |
Why?
|
| Anticarcinogenic Agents | 1 | 2013 | 249 | 0.090 |
Why?
|
| Drug Monitoring | 2 | 2018 | 960 | 0.090 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2012 | 150 | 0.090 |
Why?
|
| Apolipoproteins B | 2 | 2019 | 385 | 0.090 |
Why?
|
| Promoter Regions, Genetic | 3 | 2013 | 5779 | 0.090 |
Why?
|
| Hydrogen Peroxide | 1 | 2014 | 728 | 0.090 |
Why?
|
| Chemokine CXCL10 | 1 | 2012 | 316 | 0.090 |
Why?
|
| Endopeptidases | 1 | 2014 | 772 | 0.090 |
Why?
|
| Hyperparathyroidism | 1 | 2012 | 337 | 0.090 |
Why?
|
| Self Report | 2 | 2020 | 3714 | 0.090 |
Why?
|
| Postmenopause | 2 | 2010 | 2509 | 0.090 |
Why?
|
| Massachusetts | 4 | 2021 | 8823 | 0.090 |
Why?
|
| Energy Intake | 5 | 2023 | 2127 | 0.090 |
Why?
|
| Blood Glucose | 3 | 2010 | 6346 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 3 | 2015 | 3617 | 0.090 |
Why?
|
| Interdisciplinary Communication | 1 | 2016 | 931 | 0.090 |
Why?
|
| Fluoroquinolones | 1 | 2012 | 308 | 0.090 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2015 | 465 | 0.090 |
Why?
|
| Aging | 2 | 2007 | 8650 | 0.090 |
Why?
|
| Medication Adherence | 2 | 2013 | 2155 | 0.090 |
Why?
|
| Observer Variation | 2 | 2016 | 2600 | 0.090 |
Why?
|
| Organ Specificity | 1 | 2014 | 1955 | 0.080 |
Why?
|
| Tendinopathy | 1 | 2012 | 173 | 0.080 |
Why?
|
| Transcription, Genetic | 3 | 2013 | 7590 | 0.080 |
Why?
|
| DNA Methylation | 1 | 2023 | 4373 | 0.080 |
Why?
|
| Cholesterol, LDL | 3 | 2019 | 2374 | 0.080 |
Why?
|
| Muscle Proteins | 1 | 2015 | 1150 | 0.080 |
Why?
|
| Serine | 1 | 2013 | 828 | 0.080 |
Why?
|
| Inflammation | 4 | 2024 | 10718 | 0.080 |
Why?
|
| Cell Death | 1 | 2014 | 1668 | 0.080 |
Why?
|
| Glaucoma, Open-Angle | 1 | 2016 | 734 | 0.080 |
Why?
|
| DNA Copy Number Variations | 1 | 2017 | 2012 | 0.080 |
Why?
|
| Tendon Injuries | 1 | 2012 | 327 | 0.080 |
Why?
|
| Protein Structure, Tertiary | 2 | 2013 | 3796 | 0.080 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2015 | 1312 | 0.080 |
Why?
|
| Acute Kidney Injury | 1 | 2021 | 1926 | 0.080 |
Why?
|
| Mice | 10 | 2021 | 81101 | 0.080 |
Why?
|
| Office Visits | 1 | 2013 | 596 | 0.080 |
Why?
|
| Intensive Care Units | 2 | 2021 | 3732 | 0.080 |
Why?
|
| Cell Proliferation | 4 | 2017 | 10416 | 0.080 |
Why?
|
| Forkhead Transcription Factors | 1 | 2016 | 1611 | 0.080 |
Why?
|
| Predictive Value of Tests | 8 | 2016 | 15225 | 0.080 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2014 | 1240 | 0.080 |
Why?
|
| Mass Spectrometry | 1 | 2015 | 2189 | 0.080 |
Why?
|
| Sulfones | 2 | 2016 | 446 | 0.070 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2017 | 3216 | 0.070 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2014 | 1722 | 0.070 |
Why?
|
| Body Composition | 1 | 2017 | 2416 | 0.070 |
Why?
|
| Protein Methyltransferases | 1 | 2007 | 53 | 0.070 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2010 | 490 | 0.070 |
Why?
|
| Transcription Factors | 1 | 2007 | 12094 | 0.070 |
Why?
|
| Guideline Adherence | 1 | 2018 | 2215 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2019 | 3992 | 0.070 |
Why?
|
| Hot Temperature | 1 | 2014 | 1434 | 0.070 |
Why?
|
| Withholding Treatment | 1 | 2012 | 610 | 0.070 |
Why?
|
| Hypertriglyceridemia | 1 | 2010 | 293 | 0.070 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2014 | 1016 | 0.070 |
Why?
|
| Creatinine | 2 | 2010 | 1892 | 0.070 |
Why?
|
| Nuclear Proteins | 2 | 2016 | 5786 | 0.070 |
Why?
|
| Depression | 3 | 2022 | 8057 | 0.070 |
Why?
|
| Kansas | 2 | 2005 | 37 | 0.070 |
Why?
|
| Osteoporosis | 1 | 2017 | 1598 | 0.070 |
Why?
|
| Wine | 1 | 2007 | 166 | 0.070 |
Why?
|
| Reproducibility of Results | 6 | 2023 | 20055 | 0.070 |
Why?
|
| Smad6 Protein | 1 | 2006 | 14 | 0.070 |
Why?
|
| Neoplasms | 3 | 2023 | 22032 | 0.070 |
Why?
|
| Body Weights and Measures | 1 | 2007 | 208 | 0.070 |
Why?
|
| Receptors, Androgen | 1 | 2013 | 1077 | 0.070 |
Why?
|
| Gene Knockdown Techniques | 3 | 2016 | 1610 | 0.070 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2016 | 2053 | 0.070 |
Why?
|
| RNA Interference | 2 | 2013 | 2836 | 0.070 |
Why?
|
| Clinical Trials as Topic | 3 | 2011 | 7985 | 0.070 |
Why?
|
| Oocytes | 2 | 2024 | 1165 | 0.070 |
Why?
|
| Cell Line | 2 | 2024 | 15591 | 0.070 |
Why?
|
| Mice, Knockout | 3 | 2018 | 14354 | 0.070 |
Why?
|
| Alleles | 3 | 2014 | 6895 | 0.070 |
Why?
|
| Hypercholesterolemia | 1 | 2013 | 1138 | 0.070 |
Why?
|
| Surgical Wound Infection | 1 | 2015 | 1526 | 0.070 |
Why?
|
| Smoking Cessation | 1 | 2017 | 2055 | 0.060 |
Why?
|
| Drug Discovery | 1 | 2013 | 1044 | 0.060 |
Why?
|
| Iodide Peroxidase | 1 | 2007 | 294 | 0.060 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2018 | 1852 | 0.060 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2006 | 261 | 0.060 |
Why?
|
| Vascular Diseases | 1 | 2014 | 1160 | 0.060 |
Why?
|
| Cell Movement | 3 | 2015 | 5201 | 0.060 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2015 | 2800 | 0.060 |
Why?
|
| Treatment Failure | 2 | 2009 | 2640 | 0.060 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2015 | 1406 | 0.060 |
Why?
|
| Yogurt | 1 | 2005 | 71 | 0.060 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2015 | 2895 | 0.060 |
Why?
|
| Sepsis | 1 | 2019 | 2587 | 0.060 |
Why?
|
| Methylation | 1 | 2007 | 1080 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2013 | 8506 | 0.060 |
Why?
|
| Mitochondria | 1 | 2017 | 3584 | 0.060 |
Why?
|
| Beer | 1 | 2024 | 134 | 0.060 |
Why?
|
| Blood Pressure Determination | 2 | 2019 | 634 | 0.060 |
Why?
|
| Phosphofructokinase-2 | 1 | 2023 | 32 | 0.060 |
Why?
|
| Electronic Health Records | 3 | 2021 | 4761 | 0.060 |
Why?
|
| Labyrinth Diseases | 1 | 2005 | 151 | 0.060 |
Why?
|
| Direct Service Costs | 1 | 2003 | 60 | 0.060 |
Why?
|
| General Practitioners | 2 | 2016 | 101 | 0.060 |
Why?
|
| Administration, Oral | 3 | 2021 | 3991 | 0.060 |
Why?
|
| Probability | 3 | 2007 | 2467 | 0.060 |
Why?
|
| Lung Neoplasms | 4 | 2015 | 13245 | 0.060 |
Why?
|
| Wounds and Injuries | 1 | 2016 | 2476 | 0.060 |
Why?
|
| Regression Analysis | 2 | 2010 | 6354 | 0.060 |
Why?
|
| Osteitis Deformans | 1 | 2003 | 54 | 0.050 |
Why?
|
| Drug Therapy, Combination | 4 | 2017 | 6293 | 0.050 |
Why?
|
| Biological Availability | 1 | 2004 | 390 | 0.050 |
Why?
|
| Prostate-Specific Antigen | 1 | 2013 | 2528 | 0.050 |
Why?
|
| Coronary Artery Disease | 1 | 2023 | 6362 | 0.050 |
Why?
|
| Toll-Like Receptors | 1 | 2006 | 590 | 0.050 |
Why?
|
| Area Under Curve | 1 | 2007 | 1632 | 0.050 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2012 | 1793 | 0.050 |
Why?
|
| Observation | 1 | 2004 | 311 | 0.050 |
Why?
|
| Mass Screening | 1 | 2018 | 5427 | 0.050 |
Why?
|
| Arthrography | 1 | 2003 | 149 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3076 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 2014 | 7818 | 0.050 |
Why?
|
| Dietary Carbohydrates | 1 | 2007 | 890 | 0.050 |
Why?
|
| Educational Status | 1 | 2010 | 2513 | 0.050 |
Why?
|
| Anthropometry | 1 | 2007 | 1347 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3196 | 0.050 |
Why?
|
| Meta-Analysis as Topic | 2 | 2020 | 1373 | 0.050 |
Why?
|
| Patient Dropouts | 1 | 2024 | 412 | 0.050 |
Why?
|
| Telemedicine | 1 | 2019 | 3018 | 0.050 |
Why?
|
| Diabetes Complications | 1 | 2009 | 1317 | 0.050 |
Why?
|
| Mutation | 3 | 2016 | 29915 | 0.050 |
Why?
|
| Esophageal Neoplasms | 1 | 2012 | 1648 | 0.050 |
Why?
|
| Milk | 1 | 2005 | 443 | 0.050 |
Why?
|
| Analysis of Variance | 3 | 2012 | 6234 | 0.050 |
Why?
|
| Antineoplastic Agents | 2 | 2022 | 13591 | 0.050 |
Why?
|
| Carotid Artery, Common | 1 | 2002 | 175 | 0.050 |
Why?
|
| Diet Records | 1 | 2023 | 427 | 0.050 |
Why?
|
| Omeprazole | 1 | 2022 | 105 | 0.050 |
Why?
|
| International Cooperation | 2 | 2020 | 1430 | 0.050 |
Why?
|
| Health Surveys | 2 | 2012 | 4064 | 0.050 |
Why?
|
| Malondialdehyde | 1 | 2021 | 111 | 0.050 |
Why?
|
| Plants, Medicinal | 1 | 2021 | 165 | 0.050 |
Why?
|
| Histamine H2 Antagonists | 1 | 2022 | 165 | 0.050 |
Why?
|
| Dietary Supplements | 1 | 2013 | 3387 | 0.040 |
Why?
|
| Wrist Joint | 1 | 2022 | 265 | 0.040 |
Why?
|
| Confidence Intervals | 2 | 2020 | 2925 | 0.040 |
Why?
|
| Primary Health Care | 1 | 2017 | 4652 | 0.040 |
Why?
|
| Biological Transport | 1 | 2024 | 2084 | 0.040 |
Why?
|
| Nausea | 1 | 2022 | 677 | 0.040 |
Why?
|
| Albumins | 1 | 2022 | 575 | 0.040 |
Why?
|
| Sex Characteristics | 1 | 2010 | 2621 | 0.040 |
Why?
|
| Vancomycin | 1 | 2022 | 503 | 0.040 |
Why?
|
| Exercise | 2 | 2021 | 5788 | 0.040 |
Why?
|
| Vomiting | 1 | 2022 | 651 | 0.040 |
Why?
|
| ROC Curve | 1 | 2007 | 3563 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 9404 | 0.040 |
Why?
|
| Kidney Calculi | 1 | 2003 | 468 | 0.040 |
Why?
|
| Americas | 1 | 2019 | 111 | 0.040 |
Why?
|
| Opportunistic Infections | 1 | 2002 | 375 | 0.040 |
Why?
|
| Transforming Growth Factor beta | 1 | 2006 | 1958 | 0.040 |
Why?
|
| Cross Infection | 1 | 2008 | 1432 | 0.040 |
Why?
|
| Asthma | 1 | 2017 | 6172 | 0.040 |
Why?
|
| Electronics | 1 | 2020 | 315 | 0.040 |
Why?
|
| Phototherapy | 1 | 2021 | 368 | 0.040 |
Why?
|
| Polynesia | 1 | 2017 | 14 | 0.040 |
Why?
|
| Plant Proteins | 1 | 2020 | 369 | 0.040 |
Why?
|
| Causality | 1 | 2004 | 1241 | 0.040 |
Why?
|
| Algorithms | 2 | 2016 | 13961 | 0.040 |
Why?
|
| Endpoint Determination | 2 | 2011 | 590 | 0.040 |
Why?
|
| Microcirculation | 1 | 2023 | 1273 | 0.040 |
Why?
|
| Melanoma | 1 | 2016 | 5691 | 0.040 |
Why?
|
| Arteriosclerosis | 1 | 2002 | 1055 | 0.040 |
Why?
|
| Organic Anion Transport Protein 1 | 1 | 2017 | 6 | 0.040 |
Why?
|
| Primates | 1 | 2020 | 523 | 0.040 |
Why?
|
| Color | 1 | 2019 | 298 | 0.040 |
Why?
|
| Injections, Intra-Articular | 1 | 2019 | 279 | 0.040 |
Why?
|
| Mice, Nude | 2 | 2015 | 3602 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 9160 | 0.040 |
Why?
|
| Pharmacists | 1 | 2019 | 258 | 0.040 |
Why?
|
| Environment | 1 | 2003 | 1118 | 0.040 |
Why?
|
| Asia | 1 | 2019 | 616 | 0.040 |
Why?
|
| Histones | 1 | 2007 | 2577 | 0.040 |
Why?
|
| Uncertainty | 1 | 2022 | 751 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2019 | 677 | 0.030 |
Why?
|
| Coronary Circulation | 1 | 2023 | 1561 | 0.030 |
Why?
|
| Income | 1 | 2005 | 1872 | 0.030 |
Why?
|
| Schizophrenia | 1 | 2015 | 6910 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2020 | 3801 | 0.030 |
Why?
|
| Mental Health | 2 | 2022 | 3234 | 0.030 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2017 | 159 | 0.030 |
Why?
|
| Societies, Medical | 2 | 2019 | 3891 | 0.030 |
Why?
|
| Infectious Disease Medicine | 1 | 2016 | 49 | 0.030 |
Why?
|
| Synovitis | 1 | 2017 | 215 | 0.030 |
Why?
|
| Species Specificity | 1 | 2020 | 2417 | 0.030 |
Why?
|
| Multifactorial Inheritance | 1 | 2024 | 1365 | 0.030 |
Why?
|
| Pharmacogenetics | 1 | 2020 | 675 | 0.030 |
Why?
|
| Myocardial Revascularization | 1 | 2019 | 792 | 0.030 |
Why?
|
| Food | 1 | 2020 | 771 | 0.030 |
Why?
|
| Microscopic Polyangiitis | 1 | 2015 | 46 | 0.030 |
Why?
|
| Chi-Square Distribution | 2 | 2017 | 3425 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2004 | 1185 | 0.030 |
Why?
|
| Veterans | 1 | 2009 | 2631 | 0.030 |
Why?
|
| Leupeptins | 1 | 2015 | 113 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 2 | 2015 | 6209 | 0.030 |
Why?
|
| Phenotype | 3 | 2019 | 16534 | 0.030 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2023 | 1927 | 0.030 |
Why?
|
| Metabolic Diseases | 1 | 2021 | 682 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2020 | 799 | 0.030 |
Why?
|
| Double-Blind Method | 3 | 2017 | 12262 | 0.030 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2018 | 703 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 2014 | 6852 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2016 | 2825 | 0.030 |
Why?
|
| Water | 1 | 2021 | 1402 | 0.030 |
Why?
|
| Goals | 1 | 2020 | 707 | 0.030 |
Why?
|
| Ibuprofen | 1 | 2016 | 229 | 0.030 |
Why?
|
| Diagnosis, Differential | 2 | 2019 | 12951 | 0.030 |
Why?
|
| Medical Records | 2 | 2014 | 1406 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2022 | 2322 | 0.030 |
Why?
|
| Ischemic Attack, Transient | 1 | 2019 | 878 | 0.030 |
Why?
|
| Pulmonary Medicine | 1 | 2016 | 221 | 0.030 |
Why?
|
| State Medicine | 1 | 2015 | 213 | 0.030 |
Why?
|
| Forecasting | 1 | 2003 | 2923 | 0.030 |
Why?
|
| Adipose Tissue | 1 | 2006 | 3299 | 0.030 |
Why?
|
| Models, Economic | 1 | 2017 | 715 | 0.030 |
Why?
|
| Synovial Fluid | 1 | 2015 | 395 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2023 | 2858 | 0.030 |
Why?
|
| Etoposide | 1 | 2014 | 630 | 0.030 |
Why?
|
| Glycosylation | 1 | 2016 | 1095 | 0.030 |
Why?
|
| Protein Stability | 1 | 2015 | 566 | 0.030 |
Why?
|
| Reference Values | 1 | 2020 | 4919 | 0.030 |
Why?
|
| Nephrology | 1 | 2016 | 263 | 0.030 |
Why?
|
| Inflammasomes | 1 | 2017 | 527 | 0.030 |
Why?
|
| Interleukin-1 | 1 | 2016 | 1249 | 0.030 |
Why?
|
| Inhibins | 1 | 2012 | 209 | 0.030 |
Why?
|
| Vimentin | 1 | 2013 | 255 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2019 | 2676 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2005 | 3586 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 2021 | 2131 | 0.020 |
Why?
|
| p300-CBP Transcription Factors | 1 | 2013 | 150 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2002 | 3527 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2016 | 1593 | 0.020 |
Why?
|
| Evolution, Molecular | 1 | 2020 | 1885 | 0.020 |
Why?
|
| Internationality | 1 | 2017 | 1000 | 0.020 |
Why?
|
| Homeostasis | 1 | 2023 | 3301 | 0.020 |
Why?
|
| Pedigree | 2 | 2014 | 4578 | 0.020 |
Why?
|
| Drug Repositioning | 1 | 2013 | 231 | 0.020 |
Why?
|
| Data Collection | 2 | 2011 | 3322 | 0.020 |
Why?
|
| China | 1 | 2017 | 2333 | 0.020 |
Why?
|
| Coronary Vessels | 1 | 2023 | 3072 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2015 | 1866 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 2023 | 4451 | 0.020 |
Why?
|
| Eosinophils | 1 | 2016 | 946 | 0.020 |
Why?
|
| Rupture | 1 | 2012 | 443 | 0.020 |
Why?
|
| Chronic Disease | 2 | 2019 | 9267 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2016 | 2221 | 0.020 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2012 | 441 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2019 | 2154 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2023 | 3754 | 0.020 |
Why?
|
| Upper Extremity | 1 | 2015 | 661 | 0.020 |
Why?
|
| Child | 3 | 2009 | 79818 | 0.020 |
Why?
|
| Spinal Fractures | 1 | 2017 | 702 | 0.020 |
Why?
|
| Achilles Tendon | 1 | 2012 | 179 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2021 | 3099 | 0.020 |
Why?
|
| Glycolysis | 1 | 2014 | 826 | 0.020 |
Why?
|
| NF-kappa B | 2 | 2010 | 2472 | 0.020 |
Why?
|
| Protein Multimerization | 1 | 2015 | 979 | 0.020 |
Why?
|
| Immunoglobulin E | 1 | 2016 | 1484 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2017 | 5031 | 0.020 |
Why?
|
| Fibrosis | 1 | 2016 | 2038 | 0.020 |
Why?
|
| Cost Savings | 1 | 2014 | 918 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2019 | 2976 | 0.020 |
Why?
|
| Androgens | 1 | 2016 | 1291 | 0.020 |
Why?
|
| Apoptosis | 2 | 2014 | 9468 | 0.020 |
Why?
|
| Anxiety Disorders | 1 | 2020 | 2714 | 0.020 |
Why?
|
| Neurology | 1 | 2016 | 778 | 0.020 |
Why?
|
| Decision Making | 1 | 2002 | 3915 | 0.020 |
Why?
|
| Cadherins | 1 | 2013 | 898 | 0.020 |
Why?
|
| Ultrasonography | 2 | 2017 | 5952 | 0.020 |
Why?
|
| Exons | 1 | 2014 | 2387 | 0.020 |
Why?
|
| Polymyalgia Rheumatica | 1 | 2008 | 53 | 0.020 |
Why?
|
| Photography | 1 | 2011 | 530 | 0.020 |
Why?
|
| Temperature | 1 | 2014 | 2219 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2016 | 1878 | 0.020 |
Why?
|
| TNF Receptor-Associated Factor 6 | 1 | 2006 | 62 | 0.020 |
Why?
|
| Lung Diseases | 1 | 2016 | 1910 | 0.020 |
Why?
|
| Protein Interaction Mapping | 1 | 2010 | 616 | 0.020 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2006 | 76 | 0.020 |
Why?
|
| Neck Pain | 1 | 2008 | 186 | 0.020 |
Why?
|
| Proteins | 1 | 2021 | 6026 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2017 | 4711 | 0.020 |
Why?
|
| Dermatology | 1 | 2016 | 914 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 2016 | 1647 | 0.020 |
Why?
|
| I-kappa B Proteins | 1 | 2006 | 211 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2012 | 3612 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2021 | 3418 | 0.020 |
Why?
|
| Bone and Bones | 1 | 2016 | 2560 | 0.020 |
Why?
|
| Homocysteine | 1 | 2009 | 638 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2006 | 26183 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2013 | 6127 | 0.020 |
Why?
|
| Receptors, CXCR4 | 1 | 2010 | 727 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2014 | 4257 | 0.020 |
Why?
|
| Dietary Sucrose | 1 | 2007 | 244 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 6493 | 0.020 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2009 | 1125 | 0.020 |
Why?
|
| Anxiety | 1 | 2020 | 4539 | 0.020 |
Why?
|
| Urinalysis | 1 | 2007 | 368 | 0.020 |
Why?
|
| Carpal Tunnel Syndrome | 1 | 2008 | 303 | 0.010 |
Why?
|
| Genomics | 1 | 2020 | 5790 | 0.010 |
Why?
|
| Psychiatry | 1 | 2016 | 1689 | 0.010 |
Why?
|
| Patient Selection | 1 | 2016 | 4244 | 0.010 |
Why?
|
| Back Pain | 1 | 2008 | 543 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2017 | 36284 | 0.010 |
Why?
|
| Infant | 1 | 2006 | 36055 | 0.010 |
Why?
|
| Meniere Disease | 1 | 2005 | 163 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2015 | 3671 | 0.010 |
Why?
|
| Binding Sites | 1 | 2012 | 6036 | 0.010 |
Why?
|
| Calcium, Dietary | 1 | 2006 | 529 | 0.010 |
Why?
|
| Bone Density | 1 | 2016 | 3533 | 0.010 |
Why?
|
| Fibromyalgia | 1 | 2008 | 401 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2006 | 42062 | 0.010 |
Why?
|
| Renal Dialysis | 1 | 2012 | 1786 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2021 | 11892 | 0.010 |
Why?
|
| Drug Prescriptions | 1 | 2012 | 1668 | 0.010 |
Why?
|
| Models, Econometric | 1 | 2003 | 216 | 0.010 |
Why?
|
| Cell Survival | 1 | 2013 | 5781 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2010 | 2904 | 0.010 |
Why?
|
| Base Sequence | 1 | 2014 | 12436 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2021 | 22003 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 2014 | 2523 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2010 | 21017 | 0.010 |
Why?
|
| Skin | 1 | 2016 | 4464 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 2014 | 3561 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2013 | 3997 | 0.010 |
Why?
|
| Efficiency | 1 | 2005 | 477 | 0.010 |
Why?
|
| Anti-Glomerular Basement Membrane Disease | 1 | 2002 | 41 | 0.010 |
Why?
|
| Tunica Media | 1 | 2002 | 112 | 0.010 |
Why?
|
| Lupus Vasculitis, Central Nervous System | 1 | 2002 | 32 | 0.010 |
Why?
|
| Lung | 1 | 2020 | 9985 | 0.010 |
Why?
|
| Atherosclerosis | 1 | 2018 | 3401 | 0.010 |
Why?
|
| Brain Ischemia | 1 | 2015 | 3047 | 0.010 |
Why?
|
| Hematologic Neoplasms | 1 | 2013 | 1890 | 0.010 |
Why?
|
| Cryoglobulinemia | 1 | 2002 | 84 | 0.010 |
Why?
|
| Computational Biology | 1 | 2013 | 3502 | 0.010 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2014 | 3615 | 0.010 |
Why?
|
| Prednisolone | 1 | 2002 | 326 | 0.010 |
Why?
|
| Cytokines | 1 | 2016 | 7338 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 2015 | 3526 | 0.010 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2006 | 841 | 0.010 |
Why?
|
| Pediatrics | 1 | 2016 | 3587 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 2007 | 1788 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2013 | 9518 | 0.010 |
Why?
|
| New England | 1 | 2003 | 1053 | 0.010 |
Why?
|
| Tunica Intima | 1 | 2002 | 459 | 0.010 |
Why?
|
| Pandemics | 1 | 2020 | 8611 | 0.010 |
Why?
|
| Arteritis | 1 | 2002 | 159 | 0.010 |
Why?
|
| Boston | 1 | 2013 | 9304 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2010 | 4901 | 0.010 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2005 | 781 | 0.010 |
Why?
|
| Models, Biological | 1 | 2015 | 9460 | 0.010 |
Why?
|
| Dietary Fats | 1 | 2006 | 1991 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2012 | 5070 | 0.010 |
Why?
|
| Serine Endopeptidases | 1 | 2003 | 1020 | 0.010 |
Why?
|
| Outpatients | 1 | 2005 | 1591 | 0.010 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2006 | 1887 | 0.010 |
Why?
|
| Secondary Prevention | 1 | 2003 | 1474 | 0.010 |
Why?
|
| Age of Onset | 1 | 2003 | 3298 | 0.010 |
Why?
|
| Drug Costs | 1 | 2003 | 1178 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 2003 | 2414 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2003 | 6821 | 0.010 |
Why?
|
| Insurance, Health | 1 | 2003 | 2495 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2006 | 18940 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2005 | 6457 | 0.000 |
Why?
|